Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tourmaline Bio Inc. (TRML)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TRML (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $56.2
1 Year Target Price $56.2
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.02% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 575.25M USD | Price to earnings Ratio - | 1Y Target Price 56.2 |
Price to earnings Ratio - | 1Y Target Price 56.2 | ||
Volume (30-day avg) 11 | Beta - | 52 Weeks Range 11.56 - 29.79 | Updated Date 08/15/2025 |
52 Weeks Range 11.56 - 29.79 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.03% | Return on Equity (TTM) -26.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 336160880 | Price to Sales(TTM) - |
Enterprise Value 336160880 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -281.95 | Shares Outstanding 25692300 | Shares Floating 13925981 |
Shares Outstanding 25692300 | Shares Floating 13925981 | ||
Percent Insiders 21.93 | Percent Institutions 90.14 |
Upturn AI SWOT
Tourmaline Bio Inc.
Company Overview
History and Background
Tourmaline Bio Inc. is a clinical-stage biotechnology company focused on developing transformative medicines to benefit patients with debilitating diseases. Founded in 2022, it is dedicated to addressing unmet needs in immunology and inflammation.
Core Business Areas
- Drug Development: Focused on the development of innovative therapeutics for immune-mediated diseases.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and the pharmaceutical industry. The organizational structure is typical of a clinical-stage biotech, centered around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- TOUR006: TOUR006 is a fully human anti-IL-6 antibody designed for the treatment of thyroid eye disease (TED) and other inflammatory conditions. It's currently in clinical development. Market share data is not yet applicable as it is not commercialized. Competitors include Horizon Therapeutics (TEPEZZA).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Focus is increasingly on targeted therapies and addressing unmet medical needs.
Positioning
Tourmaline Bio is positioned as a company focused on developing innovative therapies for immune-mediated diseases. Its competitive advantage lies in its proprietary antibody technology and targeted approach to drug development.
Total Addressable Market (TAM)
The global immunology market is substantial, projected to reach hundreds of billions of dollars. Tourmaline is targeting specific segments, such as thyroid eye disease, within this larger market. Their position depends on the success of TOUR006.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Proprietary antibody technology
- Targeted approach to drug development
- Strong intellectual property position
Weaknesses
- Early-stage company with limited revenue
- High reliance on clinical trial outcomes
- Limited resources compared to larger pharmaceutical companies
Opportunities
- Successful clinical trials leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Growing demand for targeted therapies
Threats
- Clinical trial failures
- Competition from existing therapies and new entrants
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- Horizon Therapeutics (HZNP)
- Amgen (AMGN)
- Roche (RHHBY)
Competitive Landscape
Tourmaline Bio faces competition from established pharmaceutical companies with approved therapies for immune-mediated diseases. Its success depends on demonstrating superior efficacy and safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and fundraising activities.
Future Projections: Future growth is dependent on the successful development and commercialization of TOUR006 and other pipeline candidates. Analyst estimates are not available without specific financial data.
Recent Initiatives: Recent initiatives include advancing TOUR006 through clinical trials and exploring potential partnerships.
Summary
Tourmaline Bio Inc. is an early-stage biotech company with promising drug candidate TOUR006, targeting diseases like TED. Its success hinges on positive clinical trial outcomes, regulatory approvals, and effectively managing its cash runway. The company needs to be aware of competition from larger pharmaceutical companies and the risks associated with drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and is subject to change. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tourmaline Bio Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-05-07 | Co-Founder, CEO & Director Dr. Sandeep C. Kulkarni M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.tourmalinebio.com |
Full time employees 74 | Website https://www.tourmalinebio.com | ||
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.